Markets:

Overview

News

Currencies

International

Treasuries

Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

0.7000 -0.0800 (-10.26%)

Streaming Delayed Price Updated: 1:41 PM EST, Dec 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Skye Bioscience, Inc. - Common Stock

< Previous 1 2 3 4 Next >

What's going on in today's session ↗

June 23, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 23, 2025

Via Benzinga

Which stocks are experiencing notable movement on Monday? ↗

June 23, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

These stocks are moving in today's pre-market session ↗

June 23, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News ↗

April 15, 2025

Via Stocktwits

Top stock movements in today's session. ↗

April 15, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models ↗

April 15, 2025

Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential.

Via Benzinga

Tuesday's session: top gainers and losers ↗

April 15, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 15, 2025

Via Benzinga

The market is filled with gapping stocks in Tuesday's session. ↗

April 15, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

Via Chartmill

Crude Oil Moves Lower; Citigroup Posts Upbeat Results ↗

April 15, 2025

Via Benzinga

Nasdaq Surges 100 Points; Bank of America Earnings Top Views ↗

April 15, 2025

Via Benzinga

Earnings Scheduled For March 20, 2025 ↗

March 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

February 12, 2025

Via Benzinga

Tuesday's session: top gainers and losers ↗

February 11, 2025

Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Top Picks For 2025: Skye Bioscience ↗

February 02, 2025

Skye Bioscience is developing a peripheral restricted CB1 antibody to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects....

Via Talk Markets

Topics Stocks / Equities

MarketBeat Week in Review – 10/7 - 10/11

October 12, 2024

Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings

Via MarketBeat

Topics Artificial Intelligence Economy

Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar

October 09, 2024

Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.

Via MarketBeat

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

October 04, 2024

Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.

Via MarketBeat

Topics Bankruptcy

Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players ↗

September 20, 2024

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus...

Via Benzinga

US Stocks Edge Lower; FedEx Earnings Miss Views ↗

September 20, 2024

Via Benzinga

Topics Earnings

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

August 16, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

August 08, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm

August 04, 2024

From The Schall Law Firm

Via Business Wire

Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity

July 24, 2024

From Beacon Biosignals

Via GlobeNewswire

3 Biotech Stocks That Can Gain Exponentially By Leveraging AI ↗

July 02, 2024

Although fraught with risk, these biotech exposures bring enormous upside potential.

Via Talk Markets

Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 18, 2024

Via Benzinga

Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet ↗

June 10, 2024

The company is focusing on obesity treatment after its glaucoma drug failed.

Via Investor's Business Daily

Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 10, 2024

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.